****	ricocipi dato.		10/2000	SOBSTITUTE IS	Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE	10-
	ubstitute for form 1449A/PTO				COMPLETE IF KNOWN	7
1	INFORMATION DISCLOSURE			Application Number	To Be Assigned 19/5.5381	Ζ.
	TATEMENT DA	. A TO	DI ICANT	Filing Date	99.Reg d.BCT/PTO 18 OCT 2	.yu
	STATEMENT BY APPLICANT			First Named Inventor	Tan, et al.	7′
				Group Art Unit		]
	(use as many sheets	as i	iecessary)	Examiner Name		]
Sheet	1	of	2	Attorney Docket Number	21198P	)

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
		US2001/0014457		Spindel, et al.	08/16/2001	
		5,656,749		Spindel, et al.	08/12/1997	
		5,814,463		Spindel, et al.	09/29/1998	
		6,043,052		Lane, et al.	03/28/2000	
		6,143,521		Lane, et al.	11/07/2000	

			Foreign Patent Documen	t		Date of Publication of	
Examiner Initials*	Cite No.	Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	
		PCT	WO 92/16623		Berlex Laboratories, Inc.	10/01/1992	
		PCT	WO 01/10889 -		Smithkline Beecham Corp.	02/15/2001	
		PCT	WO 03/014310 '		Merck & Co., Inc.	02/20/2003	
	_						
Examin	сг		/Zachary Howard/		Date	03/05/2008	

EFS-Web Receipt date: 10/18/2005

SUBSTITUTE for PTO/SB/08A (07-05), Information of Substitution of Application (197-05), Information of Substitution (197-05), Information (197-05), Informatio

·	bstitute for form 1449B/PTO			ICHNOLETE E KNOWN		
	NFORMATION 1	DIS	CLOSURE	Application Number	To Be Assigned CT/PTO 18 OCT 2	
	TATEMENT DV	A D	DITCANT	Filing Date	October 18, 2005	
3	STATEMENT BY APPLICANT			First Named Inventor	Tan, et al.	
				Group Art Unit		
	(use as many sheets as necessary)			Examiner Name		
Sheet	2	of	2	Attorney Docket Number	21198P	

$\overline{}$		
		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	1	Fathi, et al., "BRS-3: A Novel Bombesin Receptor Subtype Selectively Expressed in Testis and Lung Carcinoma Cells", J. of Biol. Chem., Vol. 268, No. 8, pp. 5979-5984, March 15, 1993.
	7	Mantey, et al., "Discovery of a High Affinity Radioligand for the Human Orphan Receptor, Bombesin Receptor Subtype 3, Which Demonstrates That It Has a Unique Phamacology", Vol. 272, No. 41, pp. 26062-26071, October 10, 1997.
	j	Ohki-Hamazaki, et al., "Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity", Nature, Vol. 390, pp. 165-169. November 1997.
	1	Ohki-Hamazaki, et al., "Cloning and Expression of the neuromedin B receptor and the third subtype of bombesin receptor genes in the mouse", Brain Research, Vol. 762, pp. 165-172, 1997.
		Pradhan, et al., "Identification of a unique ligand which has high affinity for all four bombesin receptor subtypes", European Journal of Pharmacology, Vol. 343, pp. 275-287, 1998.
	/	Sano, et al., "Characterization of the bombesin-like peptide receptor family in primates", Genomics, Vol. 84, pp. 139-146, 2004.
		Whitley, et al., "Molecular cloning, genomic organization and selective expression of bombesin receptor subtype 3 in the sheep hypothalamus and pituitary", J. of Mol. Endocrinology, Vol. 23, pp. 107-116, 1999.

Examiner Signature	/Zachary Howard/	Date Considered	03/05/2008